| (Values in U.S. Thousands) | Jun, 2021 | Mar, 2021 | Dec, 2020 | Sep, 2020 | Jun, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 17,160 | -20,640 | -6,500 | 2,110 | -1,180 |
| Net Income Growth | +183.14% | -217.54% | -408.06% | +278.81% | -61.64% |
Inspyr Therapeutics Inc (NSPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Inspyr Therapeutics, Inc. is a biotechnology company which focuses on the discovery and development of prodrug cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate, and other cancers primarily in the United States. Its product candidates include Mipsagargin, G-115, G-114 and G-301. Inspyr Therapeutics, Inc., formerly known as GenSpera, Inc., is based in San Antonio, Texas.